DelveInsight’s, “Graft versus host disease Pipeline Insight, 2023,” report provides comprehensive insights about 60+ Graft Versus Host Disease companies and 60+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, including Graft Versus Host Disease clinical trials and nonclinical stage products. It also covers the Graft Versus Host Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Graft versus host disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Graft versus host disease clinical trials studies, Graft versus host disease NDA approvals (if any), and product development activities comprising the technology, Graft versus host disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Graft versus host disease Pipeline Insight Report
To explore more information on the latest breakthroughs in the Graft versus host disease Pipeline treatment landscape of the report, click here @ Graft versus host disease Pipeline Outlook
Graft versus host Disease Overview
Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT). Cells of the immune system are trained early to differentiate between “”self”” cells and “”non-self”” cells. The ability to recognize “”non-self”” cells depends on a set of genes knows as the histocompatibility genes that provide instructions for making a group of related proteins known as major histocompatibility complex (MHC proteins) or human leukocyte antigens (HLA).
Recent Developmental Activities in the Graft Versus Host Disease Treatment Landscape
For further information, refer to the detailed Graft Versus Host Disease Unmet Needs, Graft Versus Host Disease Market Drivers, and Graft Versus Host Disease Market Barriers, click here for Graft Versus Host Disease Ongoing Clinical Trial Analysis
Graft versus host disease Emerging Drugs Profile
Teplizumab: Prevention Bio
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, Microbiome Ecosystem Therapy. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
ASC930: ASC Therapeutics
ASC930 is an allogeneic cell therapy based on off-the-shelf Decidua Stromal Cells obtained from the fetal membrane of the maternal placenta for the treatment of acute steroid-refractory Graft-versus-Host Disease, a common complication of patients receiving allogeneic hematopoietic stem cell transplantation to treat hematologic conditions. ASC930 cells possess potent immunosuppressive properties and do not display any differentiation potential, making them an ideal immunoregulatory cell therapy.
Graft Versus Host Disease Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the Graft versus host disease (GVHD) therapies. The GVHD companies which have their drug candidates in the most advanced stage, i.e preregistration include ElsaLys Biotech.
Request a sample and discover the recent advances in Graft Versus Host Disease Ongoing Clinical Trial Analysis and Medications, click here @ Graft Versus Host Disease Treatment Landscape
Scope of the Graft Versus Host Disease Pipeline Insight Report
Dive deep into rich insights for drugs for Graft Versus Host Disease Market Drivers and Graft Versus Host Disease Market Barriers, click here @ Graft Versus Host Disease Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Graft Versus Host Disease Mergers and acquisitions, Graft Versus Host Disease Licensing Activities @ Graft Versus Host Disease Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services